Biomerica Reports 24% Revenue Decline but Achieves Net Income Turnaround in Latest Quarter

Biomerica, Inc. reported its financial results for the three months ended August 31, 2025, revealing a consolidated net sales figure of approximately $1.38 million, a decrease of 24% from $1.81 million in the same period of 2024. The decline in revenue was attributed to reduced retail market activity, lower international over-the-counter sales, and decreased demand under certain contract manufacturing agreements. Despite these challenges, the company noted an improvement in gross profit, which rose to $424,000 from $289,000 year-over-year, primarily due to a significant reduction in cost of sales, which fell to $956,000 from $1.52 million.

The company's operating expenses also saw a decrease, totaling $1.54 million for the quarter, down from $1.66 million in the prior year. This reduction was driven by lower salaries and wages following a reduction in force implemented in July 2024, as well as decreased stock-based compensation and legal expenses. Notably, Biomerica reported a net income of $2,000 for the quarter, a significant turnaround from a net loss of $1.32 million in the same period last year. This improvement was bolstered by other income of approximately $1.12 million, largely due to a one-time cash refund related to the Employee Retention Credit.

In terms of strategic developments, Biomerica has been actively pursuing the commercialization of its inFoods® IBS product, which aims to help manage gastrointestinal conditions. The company has initiated collaborations with gastroenterology physician groups to gather feedback and optimize engagement. Additionally, Biomerica received FDA clearance for its hp+detect™ test, designed to detect Helicobacter pylori infections, which is expected to enhance its product offerings in the diagnostic market.

Operationally, Biomerica's cash and cash equivalents increased to $3.05 million as of August 31, 2025, compared to $2.40 million at the end of the previous fiscal year. The company also reported a working capital of approximately $4.21 million, up from $3.14 million. However, management expressed concerns regarding liquidity, indicating that current cash levels may not be sufficient to meet operational needs over the next twelve months. To address this, Biomerica has filed a shelf registration statement allowing for the issuance of up to $20 million in common stock and has raised $912,000 in net proceeds from an ATM offering.

Looking ahead, Biomerica is focused on increasing sales, reducing expenses, and exploring additional financing options to ensure operational sustainability. The company is also evaluating opportunities for geographic expansion and product adoption, particularly in international markets. However, management acknowledged that achieving these goals will be critical to overcoming the substantial doubt about the company's ability to continue as a going concern.